Cambridge Interventional
Cambridge Interventional is a privately held Burlington, MA medical device company that develops, manufactures, and sells the CRF Radiofrequency Ablation System for minimally invasive treatment of tumors in the thyroid, liver, kidney, bone, lung, and uterus, serving interventional radiologists and specialist clinicians via direct hospital sales.
- Company typePrivate
- Founded2005
- HeadquartersBurlington, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Cambridge Interventional does
Cambridge Interventional, LLC is a Burlington, Massachusetts-based, privately held medical device company that develops, manufactures, and sells the CRF (Cambridge Radiofrequency) Radiofrequency Ablation System for minimally invasive treatment of tumors and abnormal tissue. The platform combines a reusable RF generator-pump with disposable cooled electrodes (1–5 cm active tips, 15–18G gauges, up to 27 cm shafts) and is approved for ablation across thyroid, liver, kidney, bone, lung, and uterine fibroid indications. The founder, Dr. Eric Cosman Jr., carries lineage from Bernard Cosman's 1952 Radionics era and MIT's Eric Cosman Sr., who pioneered precision temperature-sensor RF electrode technology in 1980 and the first cooled percutaneous ablation system in 1995.
The CRF system's technical differentiators include 370 watts of output power (vs. Medtronic Covidien at 200W and Osteocool at 25W), real-time audiovisual impedance feedback, an adaptive pulsing algorithm that auto-trims at 20 ohms above baseline to prevent charring, thermocouple-based tip temperature confirmation (60–80°C), and a low-imaging-artifact profile favored under CT fluoroscopy. The two-piece coaxial electrode design supports biopsy-then-ablation workflows and cost-efficient inventory stocking, with electrodes priced around $1,000 per unit versus $2,200–$2,500 for competing microwave antennae. The system holds FDA 510(k) clearance, CE mark, and other international approvals, and as of January 2025 holds Category I CPT codes (60660, 60661) for thyroid ablation in the United States.
The business model is a direct hospital-institution sale of capital equipment (RF generator-pump) plus recurring consumable revenue (disposable electrodes), supported by hands-on training and structured proctorships delivered through regional masterclasses and nine major US medical conferences. Customers are interventional radiologists, interventional oncologists, thyroid specialists (endocrinologists, endocrine surgeons, ENT), gynecologists, and their associated hospitals, with named reference sites including Hospital del Mar (Barcelona) and Ospedale Galeazzi Sant'Ambrogio (Milan). GTM is enterprise field sales augmented by clinical KOL advocacy (Dr. Damian Dupuy, Dr. Giovanni Mauri, Professor Stefano Spiezia / Save Your Thyroid) and direct-to-clinician content marketing.
Cambridge Interventional firmographics
Firmographics- Name
- Cambridge Interventional
- Legal name
- Cambridge Interventional, LLC
- Website
- https://cambridgeinterventional.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Cambridge Interventional is a privately held Burlington, MA medical device company that develops, manufactures, and sells the CRF Radiofrequency Ablation System for minimally invasive treatment of tumors in the thyroid, liver, kidney, bone, lung, and uterus, serving interventional radiologists and specialist clinicians via direct hospital sales.
- Ownership category
- akta.pro rank
Cambridge Interventional industry classification
Industry- Product category
- Interventional Radiology Medical Devices
- NAICS
- Irradiation Apparatus Manufacturing (334517)
- akta.pro primary industry
- Interventional Radiology & Image-Guided Therapy Systems (HLAHABAG)
Keywords
Where Cambridge Interventional is headquartered
LocationHeadquarters
- HQ city
- Burlington
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Cambridge Interventional business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- CRF RFA System Hardware Sales: Cambridge Interventional generates revenue primarily through sales of their CRF Radiofrequency Ablation System, which includes reusable RF generators/pumps and disposable electrodes. The generator-pump is a reusable capital device while electrodes are single-use disposables. Dr. Dupuy notes RF electrodes cost approximately $1,000 per unit compared to $2,200-$2,500 for microwave antennae.
- Training and Support Services: The company provides dedicated global training and support services to clinicians, including structured proctorships, hands-on training courses, and educational programs. This supports product adoption and ongoing customer relationships.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | RF Electrodes (Disposable) |
| One time/ perpetual license | Multi-year contract | RF Generator & Pump System (Capital Equipment) |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels6 records
Cambridge Interventional product offering
Product offeringCore offering
Cambridge Interventional develops, manufactures, and sells the CRF (Cambridge Radiofrequency) Radiofrequency Ablation System — a high-power thermal ablation platform for the minimally invasive treatment of benign and malignant tumors across the thyroid, liver, kidney, bone, lung, and uterus. The offering consists of a reusable RF Generator & Pump capital device paired with single-use disposable CRF Electrodes, accompanied by structured clinician training, proctorship, and support services.
Product overview
Cambridge Interventional offers the CRF Radiofrequency Ablation System as its core product, comprising an RF Generator & Pump and compatible Electrodes. The system is designed for precision thermal ablation across multiple clinical applications including thyroid, liver, kidney, bone, lung, and myoma (uterine fibroids). The generator features real-time audiovisual feedback, adaptive control algorithms, and hands-free operation, while the electrodes are available in multiple configurations to support diverse clinical procedures.
Differentiator
Problem solved
Functional benefit
Products and services
- CRF Radiofrequency Ablation System Cambridge Interventional's flagship radiofrequency ablation platform for treating benign, malignant, and abnormal tissue in the thyroid, liver, kidney, bone, lung, and uterus. It combines an RF Generator & Pump with compatible electrodes to deliver high-power ablation with real-time audiovisual feedback and adaptive control algorithms, targeting interventional radiologists, interventional oncologists, endocrinologists, endocrine surgeons, ENT specialists, and gynecologists performing minimally invasive tumor ablation.
- RF Generator & Pump First-of-its-kind reusable generator-pump capital device that serves as a procedural copilot during RFA procedures, providing real-time audiovisual feedback on impedance and power delivery, hands-free operation via footswitch, a touchscreen interface, and automatic electronic data logging for hundreds of procedures. Sold to hospitals and clinics as reusable capital equipment paired with disposable electrodes.
- CRF Electrodes Single-use cooled radiofrequency electrodes available in one-piece and two-piece coaxial configurations with various tip lengths (1-5 cm), gauges (15-18G), and shaft lengths (up to 27cm) for diverse ablation applications across thyroid, liver, kidney, bone, lung, and myoma procedures. Low-profile hub reduces hand fatigue and improves anatomical clearance; the two-piece design enables biopsy before ablation and cost-efficient inventory management.
- RFA Training & Support Dedicated global training and support service that provides clinicians with structured proctorships, hands-on training courses, and educational programs (including KOL-led masterclasses) to support adoption and competent use of the CRF RFA System across clinical applications.
Quantifiable outcome
- Thyroid nodule volume reduction: 94% after 10 years (Park et al. 2024 study of 421 patients)
- +8 more outcomes
Companies that use Cambridge Interventional
Customer profileNamed customers6 records
Segments6 records
Ideal customer profiles1 record
Cambridge Interventional technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature9 records
Cambridge Interventional partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- Ospedale Galeazzi - Sant'Ambrogio (Milan, Italy)coreHost institution for Thyroid RFA Masterclass on June 8-9, 2026 in partnership with Save Your Thyroid. Training led by Dr. Giovanni Mauri, Prof. Luca Maria Sconfienza, and Dr. Pierluigi Glielmo. Five clinical cases performed including benign thyroid nodules, recurrence of papillary thyroid carcinoma, and TIR3 nodule.
- Hospital del Mar (Barcelona, Spain)corePartnership for clinical education and training in thyroid radiofrequency ablation. Professor Stefano Spiezia led training and proctorship session at Hospital del Mar, including three hands-on radiofrequency thermoablation procedures. Multidisciplinary group of physicians and specialists participated.
- Professor Stefano Spiezia / Save Your Thyroid™coreCollaboration with Save Your Thyroid initiative, an international educational initiative dedicated to promoting thyroid thermal ablation. Professor Spiezia, founder of Save Your Thyroid, serves as key opinion leader providing training and proctorship programs. Focus on preserving thyroid function while reducing unnecessary surgical interventions.
- Dr. Giovanni MauricoreKey opinion leader and clinical advisor. Head of Research Laboratory on Minimally Invasive Image-Guided Treatments of the Thyroid at IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan. Provided clinical validation of CRF System and leads training programs.
Scale indicators5 records
Recent moves5 records
Expansion highlights5 records
Cambridge Interventional competitors and assessment
Company assessmentDirect peers
- Medtronic: Acquired Covidien and markets the Cool-tip RF ablation system (referenced in the company data at 200W), the most direct head-to-head competitor to Cambridge Interventional's CRF system across liver, kidney, lung, and bone tumor ablation.
- Boston Scientific: Markets the LeVeen RF ablation electrode family and broader interventional oncology portfolio, directly competing with Cambridge Interventional in image-guided tumor ablation across multiple organ systems.
- AngioDynamics: Sells the StarBurst family of RF ablation devices for soft tissue tumors, competing head-to-head with the CRF system in liver, kidney, lung, and bone indications.
- STARmed: South Korean manufacturer and one of the most established players in thyroid RFA electrodes and generators, directly competing with Cambridge Interventional in the same thyroid ablation niche.
- NeuWave Medical (Ethicon, Johnson & Johnson): Markets microwave ablation systems that compete with the CRF system in liver, kidney, and lung tumor ablation, frequently cited by KOLs as the primary non-RFA alternative.
- Merit Medical Systems: Offers RF ablation products and a broad interventional portfolio, competing with Cambridge Interventional in image-guided tumor ablation and overlapping in hospital sales channels.
Emerging players
- Olympus: Has invested in thyroid and soft-tissue RFA / ablation technologies, representing an emerging adjacent competitor particularly in international markets where Olympus endoscopy and ultrasound distribution provides leverage.
Broad incumbents
- Stryker: Large diversified medical device company with interventional and surgical platforms that overlap with image-guided ablation markets served by Cambridge Interventional.
- Johnson & Johnson (Ethicon): Parent of NeuWave Medical and broader interventional oncology assets; a well-capitalized incumbent whose microwave and emerging ablation technologies compete across Cambridge Interventional's indications.
Others
- Hologic: Focused on women's health and fibroid treatment (e.g., Acessa RF myoma ablation system), directly comparable in the uterine myoma RFA application where Cambridge Interventional also competes.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Cambridge Interventional social profiles
Digital presenceCambridge Interventional compliance and trust
Trust signalCompliance2 records
Cambridge Interventional financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cambridge Interventional leadership team
Management profileNumber of profiles
Profiles1 record
Cambridge Interventional funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cambridge Interventional M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cambridge Interventional
What does Cambridge Interventional do?
Cambridge Interventional develops, manufactures, and sells the CRF (Cambridge Radiofrequency) Radiofrequency Ablation System — a high-power thermal ablation platform for the minimally invasive treatment of benign and malignant tumors across the thyroid, liver, kidney, bone, lung, and uterus. The offering consists of a reusable RF Generator & Pump capital device paired with single-use disposable CRF Electrodes, accompanied by structured clinician training, proctorship, and support services.
Is Cambridge Interventional a public or private company?
Cambridge Interventional is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Cambridge Interventional founded?
Cambridge Interventional was founded in 2005. It employs 1 to 10 people.
Where is Cambridge Interventional based?
Cambridge Interventional is headquartered in Burlington, United States, in the North America region.
How does Cambridge Interventional make money?
Two revenue lines are on record. CRF RFA System Hardware Sales are the primary driver. The others are training and Support Services.
Who are Cambridge Interventional's main competitors?
Direct peers on record are Medtronic, Boston Scientific, AngioDynamics, STARmed, NeuWave Medical (Ethicon, Johnson & Johnson) and Merit Medical Systems. Olympus is listed as an emerging player. Broad incumbents are Stryker and Johnson & Johnson (Ethicon). Hologic is listed as an others.
Does Cambridge Interventional have an API?
No public API is recorded for Cambridge Interventional.
What industry is Cambridge Interventional in?
Cambridge Interventional's product category is Interventional Radiology Medical Devices. Its primary akta.pro industry code is HLAHABAG, Interventional Radiology & Image-Guided Therapy Systems. Its NAICS code is 334517.